期刊文献+

吉西他滨对CD34^+ CD38^-髓系白血病干细胞的增殖抑制和凋亡诱导作用 被引量:2

Effects of gemcitabine on inhibiting proliferation and inducing apoptosis of CD34^+ CD38^- myeloid leukemia stem cells
暂未订购
导出
摘要 目的:探讨与阿糖胞苷(Ara-C)结构相似的新型脱氧胞苷相似物和核苷还原酶抑制剂——吉西他滨(gemeitabine,GEM)对CD34+CD38-KG1a髓系白血病干细胞(LSCs)增殖抑制和诱导凋亡的影响。方法:流式细胞术检测急性髓系白血病KG1a细胞表面CD34和CD38的表达;24 h和持续用药软琼脂克隆形成实验观察不同浓度GEM对KG1a细胞增殖的影响,流式细胞术检测不同浓度GEM对KG1a细胞周期的影响,Annexin V/PI双染法检测不同浓度GEM对KG1a细胞凋亡的影响。结果:急性髓系白血病KG1a细胞中CD34+CD38-占(98.02±0.72)%。0.05 mg/L、0.1 mg/L和0.5 mg/L的GEM分别作用KG1a细胞24 h、48 h和72 h后,0.5 mg/L GEM作用KG1a细胞24 h后,G0/G1期细胞高于盐水对照组(P<0.05),而0.05 mg/L和0.1 mg/L GEM作用KG1a细胞24 h后,G0/G1期细胞与盐水对照组相比,差异无统计学意义(P>0.05)。0.05 mg/L、0.1 mg/L和0.5 mg/LGEM作用KG1a细胞24 h后,软琼脂培养第14 d和21d后,0.1 mg/L和0.5 mg/L组形成的克隆数,低于盐水对照组(P<0.05),0.05 mg/L GEM组14 d、21 d的克隆数与对照组相比,差异无统计学意义(P>0.05)。0.05 mg/L、0.1 mg/L、0.5 mg/L GEM和Ara-C持续作用组,软琼脂培养14 d和21d均未见集落生长,与对照组相比差异显著(P<0.05)。0.05 mg/L、0.1 mg/L GEM作用KG1a细胞后其凋亡率与盐水对照组相比,差异无统计学意义(P>0.05),而0.5 mg/L GEM作用24 h后KG1a细胞凋亡率显著高于盐水对照组(P<0.05)。结论:GEM能抑制CD34+CD38-髓系白血病干细胞增殖和克隆形成,并将CD34+CD38-KG1a细胞阻滞在G0/G1期和诱导其凋亡。 AIM : To investigate the effects of gemcitabine ( GEM), a novel analog of deoxycytidine and nucle- oside reductase inhibitor similar to cytarabine (Ara-C) in structure, on the proliferation and apoptosis of myeloid leukemic stem cells (LSCs), CD34+CD38- KGla cells. METHODS: The expression of CD34 and CD38 on the surface of acute myeloid leukemia KG1 a cells was detected by flow cytometry. The effects of GEM at various concentrations for 24 h and sustained medication for 14 d and 21 d on the proliferation and colony-forming ability of KGla cells were analyzed by soft agar colony-forming experiment. The changes of the cell cycle of KGla cells treated with various concentrations of GEM were tested by flow cytometry. The apoptosis of KG1 a cells was determined by flow cytometry with the staining of Annexin V-FITC and propidium iodide (PI). RESULTS: The percentage of CD34 ~ CD38- cells in acute myeloid leukemia KGla cells was (98.02 ± 0.72) %. Treatments with 0. 05 mg/L and 0.1 mg/L GEM for 24 h were similar to saline control group in cell cycle distribution of the KGla cells, whereas KGla cells treated with 0.5 mg/L GEM for 24 h were arrested at G0/G1 phase. After treatment with 0.1 mg/L and 0.5 mg/L GEM for 24 h, the colony numbers at 14 d and 21 d were low- er than that in saline control group. No difference of the colony numbers between the cells treated with normal saline and 0. 05 mg/L GEM for 14 d and 21 d was observed. After sustained medication with 0. 05 mg/L, 0.1 mg/L and 0.5 mg/L GEM and Ara-C for 14 d and 21 d, the colony numbers decreased as compared to saline control group. Treatment with 0. 5 mg/L GEM for 24 h increased the apoptotic rate of KG1 a cells compared with saline control group, while treatments with O. 05 mg/L and 0.1 mg/L GEM for 24 h were similar to saline control group in cell apoptosis. CONCLUSION : GEM in- hibits the proliferation and colony-forming ability, arrests the cell cycle at G0/G1 phase and induces apoptosis of CD34+CD38- acute myeloid leukemia ceils.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2013年第3期541-545,548,共6页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.30973454)
关键词 吉西他滨 KG1a细胞 细胞周期 细胞凋亡 Gemcitabine KG1 a cells Cell cycle Apoptosis
  • 相关文献

参考文献8

  • 1黎建军,古模发,刘立志,陈诗萍,张蓉,李永强.CIK细胞回输联合吉西他滨和顺铂治疗鼻咽癌放疗后肝肺转移瘤的效果及机制研究[J].中国病理生理杂志,2011,27(2):272-277. 被引量:4
  • 2Davies AM, Ruel C, Lara PN, et al. The proteasome in- hibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer:a Cali- fornia Cancer Consortium Phase Ⅰ study [ J ] . J Thorac Oncol, 2008, 3 ( 1 ) : 68- 74.
  • 3Peters GJ, van der Wilt CL, van Moorsel C J, et al. Basis for effective combination cancer chemotherapy with antimetab- olites[ J]. Pharmacol Ther,2000, 87(2-3) :227- 253.
  • 4Nieto Y, Thall P, Valdez B, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refrac- tory lymphoid malignancies [ J ]. Biol Blood Marrow Trans- plant,2012,18 ( 11 ) : 1677-1686.
  • 5She M, Niu X, Chen X, et al. Resistance of leukemic stem-like cells in AML cell line KGla to natural killer cell-mediated cytotoxicity [ J ]. Cancer Lett, 2012, 318 (2) : 173-179.
  • 6徐霜清,祝爱珍,刘成成,许婷婷,陈小宇,刘革修.盐霉素抑制耐格列卫的人慢性粒细胞白血病细胞株K562/Glv增殖并诱导其凋亡[J].中国病理生理杂志,2012,28(7):1208-1212. 被引量:6
  • 7郭坤元,姚开泰.以肿瘤干细胞为靶的免疫治疗[J].中国肿瘤生物治疗杂志,2012,19(4):343-347. 被引量:7
  • 8Giovannetti E, Mey V, Loni L, et al. Cytotoxic activity of gemcitabine and correlation with expression profile of drug- related genes in human lymphoid cells [ J ]. Pharmacol Res, 2007, 55(4): 343-349.

二级参考文献23

  • 1万德森.临床肿瘤学[M].第2版.北京:科学出版社,2006:230-237.
  • 2Wang CC,Chang JY,Liu TW,et al.Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma[J].Head Neck,2006,28(1):74-80.
  • 3Olioso P,Giancola R,Di Riti M,et al.Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours:a pilot clinical trial[J].Hematol Oncol,2009,27(3):130-139.
  • 4Wu C,Jiang J,Shi L,et al.Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer[J].Anticancer Res,2008,28(6B):3997-4002.
  • 5Weng DS,Zhou J,Zhou QM,et al.Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas[J].J Immunother,2008,31(1):63-71.
  • 6Ma BB,Hui EP,Wong SC,et al.Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms[J].Ann Oncol,2009,20(11):1854-1859.
  • 7Zhang L,Zhang Y,Huang PY,et al.Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy[J].Cancer Chemother Pharmacol,2008,61(1):33-38.
  • 8Yau TK,Lee AW,Wong DH,et al.Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma[J].Head Neck,2006,28(10):880-887.
  • 9Shao JY,Zhang Y,Li YH,et al.Comparison of Epstein-Barr virus DNA level in plasma,peripheral blood cell and tumor tissue in nasopharyngeal carcinoma[J].Anticancer Res,2004,24(6):4059-4066.
  • 10Yang X,Goldstein AM,Chen CJ,et al.Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan[J].Int J Cancer,2006,118(3):780-784.

共引文献14

同被引文献13

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部